I. 
1. 
BACKGROUND INFORMATION ON THE PROCEDURE 
Submission of the dossier 
The applicant Gilead Sciences International Limited submitted on 12 March 2004 an application for 
Marketing Authorisation to the European Medicines Agency (EMEA) for Truvada, through the 
centralised procedure. After agreement by the CHMP on 17 December 2003, this medicinal product 
has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993 as 
amended. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  Dr. I. Hudson 
Co-Rapporteur:  Dr. E. Abadie 
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 12 March 2004.  
The procedure started on 29 March 2004. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on 
28 May 2004.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 11 June 2004. 
During  the  meeting  on  27  –  29  July  2004,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 29 July 2004. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 
3 September 2004. 
The  Rapporteurs  circulated  the  Joint  Assessment  Report  on  the  applicant’s  responses  to  the 
consolidated List of Questions to all CHMP members on 13 October 2004. 
The Rapporteurs circulated a supplementary Joint Assessment Report to all CHMP members on 
11 November 2004. 
During  the  meeting  on  15  –  18  November  2004,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Truvada on 18 November 2004. The applicant provided 
the  letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on 
12 November 2004. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 21 February 2005. 
1/1 

EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
